Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net...

Related Keywords

Ireland ,United States ,Dublin ,Irish ,American ,Siggi Olafsson ,Daniel Speciale ,Derek Belz ,Joele Frank ,Michael Freitag ,Wilkinson Brimmer Katcher ,Aaron Palash ,Community Interest ,Us Drug Enforcement Administration ,Revenue Service Under Section ,Mallinckrodt Pharmaceuticals ,Company Specialty Brands ,Exchange Commission ,Advanced Launch ,Successful Uptake ,Hospital Formulary Access ,Continued Medical Community Interest ,First Quarter Net Sales ,Net Loss ,Diluted Loss Per Share ,Adjusted Diluted Earnings Per Share ,Reduced Exposure ,Demonstrating Ongoing Focus ,Disciplined Balance Sheet ,Webcast Today ,Specialty Generics ,Chief Executive ,Specialty Brands ,Coronavirus Aid ,Economic Security ,Call Participant Registration ,Investor Relations ,Private Securities Litigation Reform Act ,Internal Revenue Service ,Internal Revenue Code ,Acthar Gel ,Enforcement Administration ,Financial Condition ,Annual Report ,Quarterly Reports ,Corporate Controller ,Chief Investor Relations ,Wilkinson Brimmer ,Related Litigation Settlement ,Flows From Operating Activities ,Flows From Investing Activities ,Flows From Financing Activities ,Mallinckrodt Plc ,